153 related articles for article (PubMed ID: 20439632)
21. Surgical resection of renal cell carcinoma after targeted therapy.
Thomas AA; Rini BI; Stephenson AJ; Garcia JA; Fergany A; Krishnamurthi V; Novick AC; Gill IS; Klein EA; Zhou M; Campbell SC
J Urol; 2009 Sep; 182(3):881-6. PubMed ID: 19616232
[TBL] [Abstract][Full Text] [Related]
22. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
23. A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Rini BI; Garcia JA; Cooney MM; Elson P; Tyler A; Beatty K; Bokar J; Mekhail T; Bukowski RM; Budd GT; Triozzi P; Borden E; Ivy P; Chen HX; Dolwati A; Dreicer R
Clin Cancer Res; 2009 Oct; 15(19):6277-83. PubMed ID: 19773375
[TBL] [Abstract][Full Text] [Related]
24. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
[TBL] [Abstract][Full Text] [Related]
25. SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer.
Mayer EL; Dhakil S; Patel T; Sundaram S; Fabian C; Kozloff M; Qamar R; Volterra F; Parmar H; Samant M; Burstein HJ
Ann Oncol; 2010 Dec; 21(12):2370-2376. PubMed ID: 20497961
[TBL] [Abstract][Full Text] [Related]
26. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients.
Adotevi O; Pere H; Ravel P; Haicheur N; Badoual C; Merillon N; Medioni J; Peyrard S; Roncelin S; Verkarre V; Mejean A; Fridman WH; Oudard S; Tartour E
J Immunother; 2010; 33(9):991-8. PubMed ID: 20948437
[TBL] [Abstract][Full Text] [Related]
27. [Therapy of untreated local advanced or metastatic renal cell carcinoma. Phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated, local advanced or metastatic renal cell carcinoma (CheckMate 214 - AN 36/15 of the AUO)].
Rexer H
Urologe A; 2015 Oct; 54(10):1443-5. PubMed ID: 26350358
[No Abstract] [Full Text] [Related]
28. Pharmacokinetics of sunitinib in hemodialysis.
Izzedine H; Etienne-Grimaldi MC; Renée N; Vignot S; Milano G
Ann Oncol; 2009 Jan; 20(1):190-2. PubMed ID: 18801884
[No Abstract] [Full Text] [Related]
29. Sequential sorafenib and sunitinib for renal cell carcinoma.
Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
[TBL] [Abstract][Full Text] [Related]
30. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors in patients treated with VEGF-targeted therapies.
Choueiri TK
Clin Adv Hematol Oncol; 2010 Feb; 8(2):92-3. PubMed ID: 20386528
[No Abstract] [Full Text] [Related]
32. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
33. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
[No Abstract] [Full Text] [Related]
34. [ASCO 2008. Bevacizumab in advanced renal carcinoma].
Mansueto G; Longo F
Tumori; 2008; 94(5):15-23. PubMed ID: 19112964
[No Abstract] [Full Text] [Related]
35. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Garfield DH; Hercbergs A; Davis PJ
J Natl Cancer Inst; 2007 Jun; 99(12):975-6; author reply 976-7. PubMed ID: 17565154
[No Abstract] [Full Text] [Related]
36. Chromophobe renal cell carcinoma with prolonged response to sequential sunitinib and everolimus.
Larkin JM; Fisher RA; Pickering LM; Sohaib SA; Ghosn M; Christmas T; Cordiner RL; Gore ME
J Clin Oncol; 2011 Mar; 29(9):e241-2. PubMed ID: 21245426
[No Abstract] [Full Text] [Related]
37. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
Sire M; Wallerand H; Kilkoski F; Grenier N; Ferrière JM; Ravaud A
Bull Cancer; 2008 Sep; 95(9):813-20. PubMed ID: 18829413
[TBL] [Abstract][Full Text] [Related]
38. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
Kahl C; Hilgendorf I; Freund M; Casper J
Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
[No Abstract] [Full Text] [Related]
39. [Not Available].
Aktuelle Urol; 2015 Sep; 46(5):356-7. PubMed ID: 26394083
[No Abstract] [Full Text] [Related]
40. Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
Hainsworth JD; Spigel DR; Burris HA; Waterhouse D; Clark BL; Whorf R
J Clin Oncol; 2010 May; 28(13):2131-6. PubMed ID: 20368560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
